### Index

- **Aarskog (Aarskog–Scott) syndrome** 82
- **accuracy of measurements** 25
- **achondroplasia** 84
- **growth charts** 332
- **treatment** 94
- **ACTH see adrenocorticotropic hormone**
- **activin, puberty** 106
- **Addison disease** 107, 165
- **features** 163
- **adenocarcinoma, ovarian** 304, 305
- **adenohypophysis (anterior pituitary)** 31, 310
- **congenital disorders** 33–9
- **tumors** 31
- **multiple hormone deficiency** 168
- **tests** 311–18
- **adenoma**
- **adrenal** 297
- **ACTH-producing** 170–1
- **aldosterone-producing** 171
- **follicular** 145–6
- **pituitary** 302
- **ACTH-producing** 169–70
- **GH-producing** 96, 97
- **ADH see vasopressin**
- **adipose tissue (fat)**
- **assessment of amount (adiposity)** 72–3
- **brown, and thyroid hormones** 131
- **deposition in health and illness** 248–9
- **adipsia**
- **central diabetes insipidus** in setting of 221
- **hypernatremia and** 224–5
- **adolescents (teenagers and youths)**
- **diabetes type 1**
- **eating disorders** 291
- **hypoglycemia-related deaths in** 291
- **insulin in errors** 289
- **regimens** 276
- **obesity in** 261–2
- **long-term risks** 261–2
- **screening for** 261
- **see also puberty**
- **adrenal androgens, precocious puberty**
- due to 110, 116–17
- **adrenal cortex imaging** 155–6
- **structure and function** 151–2
- **tumors** 170–1, 297–9
- **adrenal gland** 151–74, 297–300
- **destruction** 244–5
- **functional assessment** 155–8
- **hyper-/excess secretion by** 168–72
- **assessment** 135
- **hypoglycemia in disorders of** 244–5
- **insufficiency/deficiency**/hyposecretion** 158–68
- **acute** 163, 168
- **assessment** 155
- **chronic** 163, 165–7
- **corticosteroid-induced (in leukemia patients)** 87–8
- **CRH test** 317–18
- **primary** 165, 166–8
- **secondary** 165, 317
- **signs and symptoms** 163
- **laparoscopic removal** 179
- **normal values (for hormones)** 338–9
- **tumors** see tumors
- **adrenal hyperplasia, congenital (CAH)** 51, 55–6, 116–17, 158–65, 319–20
- **diagnosis/investigations** 51, 54, 157, 319–20
- **lipoid** 158–60
- **non-classic** 116, 157, 161–2, 164–5, 318, 319
- **scoring of virilization** 49
- **sexual precocity** 116–17
- **varieties** 56
- **web links and guidelines** 69
- **adrenal hypoplasia, congenital** 38, 167
- **adrenal steroid biosynthesis pathways** 53
- **adrenalitis, autoimmune** see autoimmune disease
- **adrenarche** 107, 116, 155
- **premature** 116
- **regulation** 155
- **adrenergic blockers, pheochromocytoma** 300
- **adrenocorticotropic hormone (ACTH; corticotropin)** 37, 152, 154
- **circadian rhythms** 154
- **in CRH test** 317
- **deficiency/insufficiency** 158, 165, 168, 256
- **cancer therapy** 88, 89
- **combined with other hormone deficiencies** 41
- **isolated** 37
- **dexamethasone-suppressed secretion, measurement** 167
- **excess** 168–71
- **ectopic sources** 168, 170, 171, 318
- **hereditary unresponsiveness to** 167
- **normal values** 338
- **stimulation test** 157
- **using ACTH(1–24)** 157, 318–19
- **adrenoleukodystrophy** 166–7, 244
- **adult life**
- **obesity risk in adolescent obesity and** 261
- **fetal environment and** 252
- **transition to care in see transitional care age**
- **bone, assessment** 73
- **gestational, small for see small for gestational age**
- **of onset diabetes** 271
- **hypoglycemia, clinical significance** 232
- **aging adult, reference ranges** 27
- **agranulocytosis, antithyroid drug-induced** 142
- **Albright hereditary osteodystrophy** 11, 185, 252
- **Albright syndrome (McCune–Albright syndrome)** 7, 113–14, 204, 206
- **aldosterone** 155
- **measuring secretion rates** 156
- **normal values** 339
- **see also renin–angiotensin–aldosterone system**
- **aldosterone synthase (P450c11AS)** 6, 165
- **deficiency** 159
- **aldosteronism (hyperaldosteronism)**
- **adrenal adenoma** 171
- **glucocorticoid-remediable** 6, 165
- **alkaline phosphatase** 176
- **normal values** 341
- **allellic association** 5
- **allergy, insulin** 288
- **Allgrove syndrome** 167
- **amiloride in nephrogenic diabetes insipidus** 223

---

anastrozole, gonadotropin-dependent 113
androgens
adrenal, precocious puberty due to 110, 116–17
females, excess 50
insensitivity syndrome (males) 55
complete 54, 320
partial 54, 320
males
deficient action 50, 52–4
deficient synthesis 50, 52
receptors 23
see also anitandrogens
androstenedione, normal values 339
Angelman syndrome 11
anthropometry 71–3
anosmia of Kallman syndrome 38, 97, 123
anorectic drugs 263–4
angiotensin 155
Angelman syndrome 11
antihypertensive drugs in diabetics 293
antiandrogens, polycystic ovaries 120
antiandrogens, self, antibodies to
for immunoassays 24, 25
self (autoantibodies)
arginine vasopressin 220
thyroid components 64, 131, 133,
135–6, 138, 139, 140, 141
see also autoimmune disease
antiandrogens
for immunoassays 24
self, antibodies to see antibodies
anorectic drugs
arthropathy
arginine stimulation test 314
arginine vasopressin 220
arginine vasopressin, functional tests 272
bicarbonate
administration in diabetic
bicarbonate
bioinformatics 2
biopsy, bone 185
birthweight, low, and obesity 253
bisphosphonates 207–8
osteoporosis 202, 208
Blood and bone turnover markers 185
Bloom syndrome 82
bone
body composition (growing child) 72–3
puberty 103
bone fluids, hormone measurements 23–30
body mass index 73
puberty 106
antithyroid medication 141–3
maternal antithyroid medication
neonatal hypothyroidism due to 64
side-effects/toxicity 142–3
Antley–Bixler syndrome 164
APECED (type 1 autoimmune
polyendocrine/polyglandular syndrome) 134, 166, 187
aquaporins (AQPs) 216, 223
mutations 223
arachnodactyly, Beals contractual 95
arginine stimulation test 314
arginine vasopressin 220
aromatase (P450aro) 153
deficiency 103
tall stature 97
aromatase inhibitors
gonadotropin-dependent precocious puberty 113
McCune–Albright syndrome 114
short stature 92, 126
arrays and microarrays, DNA 5, 9, 13
arrhythmias in hypokalemia (of diabetic
ketoacidosis) 284, 285
arterial calcification of infancy, generalized 205
L-asparaginase 87
association studies (genetic) 5
gene-wide (GWAS) 12
atrial natriuretic peptide (ANP) 216, 217
ATRX syndrome 52
autoantibodies see antibodies
autoimmune diabetes insipidus 220
autoimmune diseases
adrenals (adrenalitis) 165–6
hypoglycemia 244
diabetes mellitus type 1 and other 272
thyroid (chronic lymphocytic/
Hashimoto’s thyroiditis) 134, 135, 138
cancer risk 145
Turner girls 80
see also antibodies
autoimmune polyendocrine/
polyglandular syndrome (APS)
type 1 (APECED) 134, 166, 187
type 2 (Schmidt syndrome) 135, 166
autosomal disorders 9–10
Bardet–Biedl syndrome 252
bariatric surgery 264–5
Barter syndrome 82
Beals contractual arachnodactyly 95
Beckwith–Wiedemann syndrome 96,
241, 297
β-blockers, pheochromocytoma 300
β-cells
destruction 268
functional tests 272
bicarbonate
blood
hormone measurements 23–30
sampling for 28, 310
hormone transport 16
ketones see ketones
volume see volume
Bloom syndrome 82
body composition (growing child) 72–3
puberty 103
body fluids, hormone measurements 23–30
body mass index 72–3
obesity and 249, 262
bone
age, assessment 73
biopsy 185
cells 180–3
metabolism 179–83
metabolism, disorders 184–5,
199–205
drug therapy see drug therapy
investigation 184–5
mineral 180
mineral density
assessment 184–5
increased 202
low 200–2
puberty 100–3
mineral deposition
(mineralization) 179
puberty 100
in obesity, increased maturation 260
parathyroid hormone and 177
thyroid hormone and 131
turnover markers 185
boys
body mass index 73
puberty 106
delay 120, 124–6
physical changes 100, 101
precocious 108, 113, 114
sex steroid priming 311
syndrome-specific growth charts
achondroplasia 332
hypochondroplasia 334
Noonan syndrome 330
Prader–Willi syndrome 335, 336
Silver–Russell syndrome 331
trisomy 21 326–7
target height 74
see also males
Brachmann–de Lange syndrome 82
BRAF and thyroid cancer 145
brain
congenital anomalies causing central
diabetes insipidus 219
development, and thyroid
hormones 130–1
hypoxic injury causing diabetes
insipidus 220–1
imaging see neuroimaging
infections causing diabetes
insipidus 219
trauma see head
tumors causing diabetes
insipidus 219–20
see also central nervous system lesions;
neurological effects and entries
under cerebral
brain natriuretic peptide (BNP) 216, 217
breast
female development 100, 102
abnormalities 115–16
see also thelarche
male enlargement 100
breastfeeding
maternal antithyroid medication
and 66
obesity and 253
brown adipose tissue and thyroid
hormones 131
calcitriol

calcium

coronary artery disease (CAD) 190–1, 295

corticotropin-releasing hormone (CRH) 37, 154
testing 158, 317–18
cortisol (hydrocortisone)
day curve 319

deficiency causing hypoglycemia 244
mineralocorticoid effect 173
normal values 338
secretion in adrenal hyperfunction 320
circadian rhythms 154, 320
dexamethasone suppression test 167, 320
measuring rates of 156
in synacthen tests 318, 319
Cosyntrin (synacthen; ACTH(1–24)) test 157, 318–19
cranial (central) diabetes insipidus 39–40, 218–22
cranial irradiation (CI) and/or craniospinal irradiation (CI/CSI)
pubertal precocity 108
short stature 87, 88
evaluation 89

craniofacial dysmorphism 154, 218

craniosynostosis 218–22, 228
defects 39, 116
chondrodysplasia

corticotropin see adrenocorticotropic hormone
corticotropic-releasing hormone (CRH)

cosyntropin (synacthen; ACTH(1–24))
cranial irradiation (CI) and/or craniospinal irradiation (CI/CSI)
pubertal precocity 108
short stature 87, 88
evaluation 89

craniofacial dysmorphism 154, 218

craniosynostosis 218–22, 228
defects 39, 116
chondrodysplasia
cytogenetic abnormalities see chromosome abnormalities
Dahlborg–Borer syndrome 187
DAX-1 mutation 38, 167
DDAVP see desmopressin
de Lange syndrome 82
deaths (mortalities) in diabetic ketoacidosis 286
in bed 291
dehydration
diabetic ketoacidosis 282–3
hypernatremic 224, 225
dehydropiandrosterone (DHEAS), normal values 339
deiodination 133
deletions
chromosome 9
gene 6
Denys–Drash syndrome 51
20,22-desmolase (P450scc) deficiency 158
desmopressin (DDAVP)
in diabetes insipidus
diagnostic use 217–18
therapeutic use 221, 222
in hypernatremia 224
development
brain, and thyroid hormones 130–1
disorders see congenital disorders
hypothalamo-pituitary 32–3
obesity with delay in sex development
thyroid gland 130
dexamethasone
in 21-hydroxylase deficiency 162
suppression tests 157, 171, 320
dextrose see glucose, infusions
diabetes insipidus (DI) 45, 217–23
central (CDI) 39–40, 218–22, 228
cerebral salt wasting (CSW), distinction 228, 229
idiopathic 221
neonatal 58
nephrogenic see nephrogenic diabetes insipidus
diabetes mellitus 257–9, 267–95, 269
typical (ADN), characteristics (compared with other forms) 269
classification (by etiology) 268–71
definition and diagnosis 267–8
diabetes insipidus vs 217
gestational 252, 253, 261
ketoacidosis see ketoacidosis
maturity onset in the young see maturity-onset diabetes of the young
other specific types 268, 270–1
presentation 273
secondary causes 271
type I 267–95
acute complications 281–91
chronic/long-term complications 291–3
distinction from type 2 273–4
epidemiology 271–2
management 274–9, 282–8
prediction and prevention 272
type 2 257–9, 272–3
characteristics (compared with other forms) 269
distinction from type 1 273–4
insulin administration 279
DIDMOAD syndrome (Wolfram syndrome) 10–11, 40, 167, 218–19, 271
diet
in diabetes mellitus
hypoglycemia relating to interventions 279–80
history, and hypoglycemia 232
in obesity as cause 253
interventions 262
preventive measures 265
DiGeorge disease 186–7
dihydrotestosterone, normal values 340
1,25-dihydroxyvitamin D (1,25(OH)2D; calcitriol) 175, 178
administration 207
pseudohypoparathyroidism 190
receptor (calcitriol/vitamin D/VDR) defects 23, 193, 194
1,25-dihydroxyvitamin D-resistant rickets 193
dilated cardiomyopathy, vitamin D deficiency rickets 192–3
dipsogenic polydipsia 223
disomy, uniparental 11
distal renal tubular acidosis 193
diuretics in nephrogenic diabetes insipidus 223
DNA analysis see genetic testing mitochondrial, disorders related to see mitochondrial disorders
mutations see mutations
sequencing, novel techniques 13
transcription see transcription dominant disorders
autosomal 9
X-linked 10
dopamine agonists, GH-producing pituitary tumors 98
Down syndrome (trisomy 21)
growth charts 326–9
growth failure 80
drug history, hypoglycemia 232
drug-induced conditions
diabetes insipidus 222, 223
diabetes mellitus 271
goiter 136
obesity 255
short stature 86
water clearance impairment 227
drug therapy (pharmacotherapy)
bone metabolism disorders 207
osteoporosis 202
calcium disturbances 207–8
hyperthyroidism 141–4
obesity 263–4
pituitary tumors
ACTH-producing 170
GH-producing 98
polycystic ovaries 119–20
precocious puberty
gonadotropin-dependent 113
gonadotropin-independent (in McCune–Albright syndrome) 114
see also specific (types of) drugs
dual energy X-ray absorptiometry (DEXA) 184–5
dynamic mutations 6
dyslipidemias 259
in diabetes 292, 293
dysmorphic syndromes 94–6
symmetrical overgrowth 95–6
eating disorders
hypoglycemia with 246
type 1 diabetes and risk of developing 291
edema, cerebral, in diabetic ketoacidosis 283, 286
Edward syndrome 80
Eiken skeletal dysplasias 188
elderly (aging adult), reference ranges 27
electrolytes 210–11
administration in diabetic ketoacidosis 282–4
disturbances 224–9
normal values 340
encephalitis, pituitary dysfunction 46
endochondral bone 179
energy, ketones as source of 237, 246
see also caloric restriction
enteropancreatic islet cell tumors 301, 302
environmental factors, obesity 250, 252–3
enzymes, steroidogenic see cytochrome P450 steroidogenic enzymes
epigenetics 2, 3–4, 7, 11
see also imprinting
ergocalciferol 177
estradiol, normal values 339
see also ethinyl estradiol
estrogen(s)
administration
in pubertal delay 126–7
in short stature 92, 92–3
in tall stature 98
at puberty 71, 103, 105–6
estrogen receptor 23
mutations 103
tall stature 97
ethinyl estradiol administration
sex steroid priming with 311
in short stature 92
ethnicity/race and obesity 250, 253
examination
growth disorders 77
hypoglycemia 232
familial benign hyperparathyroidism 188
familial isolated hypoparathyroidism 188
familial primary hypomagnesemia 189
familial glucocorticoid resistance 171
familial hypomagnesemia with nephrocalcinosis 189
familial isolated hypomagnesemia 189
familial glucocorticoid deficiency 167
familial hypomagnesemia with hypercalcemia and nephrocalcinosis 189
familial autosomal-dominant neurohypophyseal DI 218
familial malignant hyperparathyroidism 189
familial primary hypomagnesemia 189
familial tall stature 97
family history, hypoglycemia 232
Fanconi syndrome 82, 206
fasting studies
fat
body see adipose tissue
diabetes, dietary 280
fatty acids
free, low and high plasma concentrations 235
oxidation defects 245, 246
FBN (fibrillin) gene abnormalities 95
feeding difficulties, congenital hyperinsulinism 243
females
pseudohermaphroditism 49
virilization see virilization
XY see XY female
sex see sex women; XX female
feminization
adrenal tumors 171
testicular (complete androgen insensitivity syndrome) 54, 320
fertility
cancer therapy and 90
treatment, boys 126
fetus
adrenal steroidogenesis 152–3
calcium metabolism 67–8
diagnosis in see prenatal diagnosis
growth
normal 70
restriction/retardation
(IUGR) 70–1, 83
hypothyroidism 61
obesity in later life related to fetal environment 252
see also development; pregnancy
FGF23 see fibroblast growth factor 23
diabetes, dietary, and diabetes mellitus 280
fibrillin gene abnormalities 95
fibroblast growth factor 23 (FGF23) 175, 178–9
excess 176, 202–4
fibrolyplasia ossificans progressiva 207
fibrous dysplasia, polyostotic 206
FIGO (International Federation of Gynecology and Obstetrics) classification, ovarian tumors 305, 306
fine needle aspiration of thyroid 147–8
carcinoma 144–5
adenoma 145–6
aspiration of thyroid 147–8
fine needle aspiration of thyroid 147–8
fluorocortisone, 21-hydroxylase deficiency 162
fluid administration
infusion
insulin deficiency 162
fluid restriction in hyponatremia 227
folic acid, dietary, and diabetes mellitus 280
folic acid in short stature 92
sex steroid priming with 311
normal values 337
puberty 104–5, 106
receptor mutations 8
follicular cells, thyroid 130, 131, 132
tumors arising from adenoma 145–6
carcinoma 144–5
Frasier syndrome 51
FTO and obesity 250–2
G (guanine-binding) proteins 20–1
receptors coupled to (GPCR) 19–22
kisspeptin and GPR54 104
mutations 21–2
second messengers 21
see also GNAS1
gain-of-function mutations 7
galactosemia, hypoglycemia in 246
gas chromatography 25
gastric surgery for weight loss 264–5
gastrinomas 302
gene(s) 3–4
conversion 5
linkage 6
see also association
polymorphisms see polymorphisms
structure and function 3–4
see also monogenic disorders;
mutations; polygenic disorders;
 pseudogenes
gender disorders (and mutations)
diabetes insipidus in central 218–19
nephrogenic 222–3
diabetes mellitus in 268, 270, 273
hypercalcemia in 182, 182, 196–7
hypocalcemia in 182, 186–9
hypoglycemia in, diagnosis 236
hypomagnesemia in 189, 191
hypothalamic–pituitary axis 35
maturity-onset diabetes of the young 270
obesity in 252
monogenic causes 255
screening 255
parathyroid gland disorders in 186–7,
196–7
pubertal delay in 123
steroidogenesis 55–6, 124, 158–65
hypoglycemia 244
thyroid hormone synthesis 136
see also syndromic associations
genetic factors in obesity 250–1
genetic testing (incl. DNA analysis) 4–5,
322–3
for multiple endocrine neoplasia
type 1 301–2
type 2 302–3
genetics
1
12
145
tumor
ovaries 305, 306
testes 306
gestation
molecular see molecular biology/
genetics
genitalia
anomalies/ambiguities see sex
development, disorders
growth at puberty 100
boys 100, 101
gene (and its study - genomics) 1–3
genome-wide association studies (GWAS) 12
germ cell tumors
ovaries 305, 306
testes 306
gestational diabetes mellitus 252,
253, 261
ghrelin 71
gigantism 96
females
sex see sex women; XX female
glycated hemoglobin (HbA1c) levels 274,

glutamate dehydrogenase (GLUD1) deficiency (gene mutations) 236, 242
glucagon administration in hypoglycemia 290–1
deficiency 244
stimulation test 235–6, 313–14
glucocorticoids (often referred to as corticosteroids or steroids) administration 172–3
adverse effects 87, 168
clinical uses other than replacement 172–3
21-hydroxylase deficiency 57, 162–3
as replacement therapy see subheading below
familial deficiency 167
familial resistance 171
hyperaldosteronism suppressed by 6, 165
hypertension suppressed by 165 receptors 23
replacement therapy 172
assessment 319
stress doses 173
withdrawal 173

glucokinase mutations 7, 242, 243
gluconeogenesis defects 245
fed and fasting child 238
glucose blood levels see glycemia
drinks in insulin tolerance test 313
homeostasis 321–2
assessment 321–3
disturbances see hyperglycemia;
hypoglycemia in fasted administration, infant/child see fasting
in fed administration, infant/child 237–9
neonatal/infantile 58–9
infusions (dextrose) in diabetic ketoacidosis 283–4
in hypoglycemia 234, 290, 291
intolerance (impaired tolerance) 257–9
progression to type 2 diabetes 257–9, 273
screening 261
tolerance test 236, 321–3

glycated hemoglobin (HbA1c) levels 274, 275, 281

gluconeogenesis (glycogenic metabolism) from (glycogenesis), fed and fasting child 238
hepatic release/storage, defects 245
glycosylation disorders, congenital 242, 243
GNAS1 (Gsα-subunit)-linked disorders 11, 23, 177, 185, 204, 205, 207
McCune–Albright syndrome 11, 113
goiter 136, 138–9
asymptomatic 138–9
drug-induced 136
non-toxic 139
gonad(s) 320–1
cancer therapy affecting 89–90
development disorders 50
females 50
males 50, 51–2
normal values (for hormones) 339–40
sex steroids see sex steroids
tumors see tumors
gonadal dysgenesis 51–2
mixed/multiple 51, 80
gonadotropin, human chorionic 320–1
administration in boys 126
stimulation test 54–5, 55, 320–1
tumors producing, sexual precocity 117
gonadotropin(s), pituitary 37–8
deficiency combined with other hormone deficiencies 41
isolated 38–9, 122–3
precocious puberty dependent on 108–13
precocious puberty due to abnormal secretion patterns 110, 115
precocious puberty independent of 110, 113–14
puberty 104–5, 106
see also follicle-stimulating hormone; luteinizing hormone
gonadotropin-releasing hormone (GnRH) 38
inactivating mutations 39
puberty 104, 106
mutation associated with pubertal delay 123
stimulation test 316–17
delayed puberty 124
precocious puberty 110
gonadotropin-releasing hormone (GnRH) agonists/analogs
precocious puberty 111–13
short stature 92
Graves disease 134, 136, 139–40, 141, 142
clinical manifestations 140
laboratory manifestations 140–1
maternal 64
neonatal 66–7

growth 70–98
disorders 70–98
examination 77
growth rate increase in obesity 96–7, 260
history-taking 76
normal definition 74–5
phases 70–1
puberty 71, 100, 103
growth charts 74–5
how to use 75–6
syndrome-specific 75, 325–36
growth failure
primary 76, 77–84
radiological investigations 315
secondary 76, 84–6
type 1 diabetes 291
growth hormone (GH) 33–6
cell surface receptors 18
abnormalities 42
circulating receptor (GH-binding protein) 19
growth hormone deficiency (GHD) 84–5, 311
acquired 44, 88
cancer therapy 88, 89
clinical features 85
hypoglycemia 244
investigations 40
isolated/primary (congenital) 34–6, 85
obesity 254
sexual precocity 108
short stature 84–5
testing 85, 311, 314, 315
excess 315
pituitary tumors 96, 97–8
tests 315, 322, 323
gene deletions 6
insensitivity 19, 42, 43, 85–6, 315
signal transduction abnormalities 19, 42, 86
treatment 94
normal values 337
profiling 29
stimulation test 30
therapeutic use in short stature 90–1
small for gestational age-borne children 83
Turner syndrome 92
growth hormone-release hormone (GHRH) 71
growth plate, cartilage 179, 180
guanine-binding proteins see G proteins
hair, pubic see pubic hair development
HAIR-AN syndrome 97
haploinsufficiency 7
haplotype determination 5
Hashimoto’s thyroiditis see autoimmune disease
head
injury (and brain injury) 5
diabetes insipidus 220
pituitary dysfunction 44–5
size measurement and charts 72
achondroplasia 332, 333
see also cranial irradiation
heart
arrhythmias in hypokalemia (of diabetic ketoacidosis) 284, 285
disease in vitamin D deficiency 5
rickets 192–3
height (length)
measurement 72
target (for boys and girls) 74
velocity (change with time) 75
puberty 100
see also growth charts; short stature; tall stature
hemoglobin levels, glycated (HbA1c) 274, 275, 281
hepatitis, antithyroid drug-induced 142
see also liver; steatohepatitis
hepatocyte nuclear factor 4α (HNF-4α) mutations 242, 243
hepatomegaly, neonatal 58–9
hereditary disorders see genetic disorders
hermaphroditism 49
true 52
HESX1 mutations 3, 34, 168, 219
histiocytosis, Langerhans cell (LCH) 45, 220
history-taking in hypoglycemia 232
histrelin, precocious puberty 111, 112
HNF-4α (hepatocyte nuclear factor 4α) mutations 242, 243
homocystinuria, tall stature 94
hormone(s) 15–30
biosynthesis/storage/secretion 15–16
defects, DNA analysis 322
counterregulatory, hypoglycemia due to failure of 244
measurements see tests
obesity due to disorders in 253–5
screening 255
receptors 16–23
assays 24
genetic defects 322–3
rhythms with 16
transport in blood 16
hormone replacement therapy (estrogen), pubertal delay 126–7
human chorionic gonadotropin see gonadotropin, human chorionic
human genome and its sequencing 3
Huntington’s disease 6
hydrocortisone see cortisol
1α-hydroxylase (25OHD) see 25-hydroxyvitamin D
1α-hydroxylase
11β-hydroxylase (CYP/P450c11B) 153
deficiency 56, 159, 160, 164–5, 319, 320
sexual precocity 116
overexpression 6
17α-hydroxylase/17,20-lyase (CYP/P450c17) 153
deficiency 159, 160–1
21-hydroxylase (CYP/P450c21) 153
deficiency 56–7, 159, 161–4, 320
sexual precocity 116
types 161–2
24-hydroxylase (25OHD) see 25-hydroxyvitamin D
24-hydroxylase
17-hydroxyprogesterone (17-OHP), 24-hydroxylase (25OHD)
25-hydroxyvitamin D
3β-hydroxysteroid dehydrogenase 56, 160, 319
deficiency 159
11β-hydroxysteroid dehydrogenase type II deficiency or impairment 23
17β-hydroxysteroid dehydrogenase 153
deficiency 52, 320
25-hydroxyvitamin D 177–8
normal values 342
25-hydroxyvitamin D
1α-hydroxylase 178
deficiency 193
25-hydroxyvitamin D 24-hydroxylase 178
deficiency 194
hyperaldosteronism see aldosteronism
hyperammonemia, syndrome of hyperinsulinism and 242, 243
hypercalcemia 182, 183–4, 195–9
causes 182, 185–95
neonatal/infantile 67, 183
familial isolated primary 195, 197
familial tumoral calcinosis 204
 homozygous 204
hypoaldosteronism 204
familial 204
management 207
hypermagnesemia 207
in insulin-dependent diabetes (Type I) 280
neonatal/infantile 67, 183
specific causes 240–6
hypercalcemia 207
hyperinsulinism 240–3
congenital (CHI) 59–61, 234, 237, 240, 241, 243
rare causes 244
hyperlipidemias see dyslipidemias
hypernatremia 224–5
hyperparathyroidism 198
hydration and treatment 198
familial isolated primary 195, 197
multiple endocrine neoplasia and 195, 302, 304
neonatal primary 68, 196
severe 195, 196
tertiary 199
hyperparathyroidism
familial tumoral calcinosis 204, 207
hyperprolactinemia 315–16
obesity and 254
pituitary tumors causing 203
testing 315–16
hypertension
in diabetes 292, 293
glucocorticoid-suppressible 165
in obesity 259
hyperthyroidism 139–44
clinical manifestations 140
laboratory manifestations 140–1
management 141–4
neonatal 66–7
tall stature 97
see also thyrotoxicosis
hypovolemia 225
hypoponatremia and 228–9
hypocalcemia 182, 183, 185–95
causes 182, 185–95
neonatal/infantile 67, 183
hypochondroplasia 84
growth charts 334
management 94
hypodipsia, central diabetes insipidus in setting of 221
hypoglycemia 39–61, 230–47,
clinical features (and symptoms and signs) 231–2, 289–90
consequences 236–7
definition 231
insulin-induced 288–91
in assessment of adrenal function 157
investigations 235–6, 321, 323
urgent 232–3
management 234, 290–1
prevention in diabetes 280
neonatal/infantile see infants
specific causes 240–6
hypogonadism 81, 97
hypergonadotropic 124–5
hypergonadotropic see hypogonadism
hyperparathyroidism 204
tall stature 97
hypogonadotropic hypogonadism 38, 39, 40, 52, 122–3
delayed puberty 122–3, 126
tall stature 97
treatment in boys 126
hypokalemia in diabetic ketoacidosis 284
hypomagnesemia, genetic causes 189
hyponatremia 225–9
hypomagnesemia, genetic causes 189
hypokalemia in diabetic ketoacidosis 284
hypogonadotropic hypogonadism 38, 39, 126
hypovolemia 215, 225
hypothyroidism 134–9
insipidus 220
polydipsia 223
short stature 86
imaging/radiology
adrenal cortex 155–6
adrenocortical tumors 297
brain see neuroimaging
calcium disorders 183–4
growth failure 315
hyperinsulinism 243
metabolic bone disorders 184–5
parathyroid tumors 198
thyroid cancer 147, 303
vitamin D deficiency rickets 192
see also specific modalities
immobilization, hypercalcemia with 198–9
immunoassays 24–8
competitive vs non-competitive 24
imprinting 11
syndromes with growth failure 81–2
incretin effect 239
infants incl. neonates 48, 48–69
immobilization, hypercalcemia with 198–9
imaging/radiology
hypophosphatemia 197, 199
hypophosphatasia 197, 199
hypophosphatemia
in diabetic ketoacidosis 285
rickets 204
hypophysitis 45
hypopituitarism 40–2
acquired 44, 45
clinical features 32, 57–8
congenital 32, 40–1, 57–8
diagnosis 41
idiopathic 168
infants 40, 57–8
see also panhypopituitarism
hypothalamo-pituitary axis 31–47
development 32–3
disorders 31–46
infant 57–8
obesity 254
hypothalamo-pituitary–adrenal axis
loops 105
precocious puberty and 108
hypothalamo-pituitary–gonadal axis
feedforward and feedback
hypothalamus 31–2
obesity and damage or disease in 254
tumors see tumors
vasopressin secretion 212
hypothyroidism 134–9
acquired 134–9
cancer therapy-related 89
clinical manifestations 137
obesity 254
congenital 61–6
thyroid cancer association 146
web links and guidelines 69
fetal 61
hypovolemia 215, 225
hyponatremia and 227–8
thirst increase 216
hypoxic brain injury causing diabetes
insipidus 220–1
Index

IPEX syndrome 270
islet cells
β-cells see β-cell
tumors (enteropancreatic) 301, 302

Jansen’s metaphyseal chondrodysplasia 195, 197
joint mobility in type 1 diabetes, limited 291
juvenile osteoporosis, idiopathic 200–201
juvenile Paget disease 202

Kabuki makeup syndrome 82
Kallman syndrome 38, 97, 123
Kearns–Sayre syndrome 186, 270
Kenny–Caffey syndrome 187
ketoadiposis, diabetic (DKA) 273, 281–8
investigating cause 285–6
management 274, 282–8
morbidly and mortality 286
pathophysiology 282
ketonuria
gonadotropin-dependent precocious puberty 113
McCune–Albright syndrome 114
ketones (and ketone bodies)
blood/plasma concentrations
fed and fasting child 238
insulin supplementation related to 287
low and high 235
testing 281
as energy sources 237, 246
synthesis/utilization, defects 245, 246
urinary see urine
ketotic hypoglycemia, idiopathic 246
kidney
chronic failure, hypocalcemia 193–5
diabetic disease 292
distal tubular acidosis 193
mineral handling 175–6
parathyroid hormone and 177
Turner syndrome 80
vasopressin and the 215–16
see also nephrogenic diabetes insipidus
KIR6.2 mutations 13, 240, 242, 270
kisspeptins 39, 104, 107
Klinefelter syndrome 52, 94, 124–5
Klotho (KL) 179, 207
Kowarski syndrome 85

labial adhesion 49–50
lactating mothers, antithyroid medication 66
Langerhans cell histiocytosis (LCH) 45, 220
laparoscopic surgery
adrenalectomy 179
ovarian tumors/cysts 114, 305
pheochromocytoma 300
Laron syndrome 19, 86, 91, 314–15
length see height
leprechaunism 271
leptin 255–6
congenital deficiency 255–6
receptor deficiency 256
role 255–6
puberty 106–7
letrozole, McCune–Albright syndrome 114
leuprolide
precocious puberty 111, 112
stimulation by (as replacement for GnRH) 317
Leydig cell failure 124
tumors 117, 306
lifestyle interventions in obesity 262–3
liver
lactinizing hormone (LH) 37–8
lack in males 52
normal values 338
puberty 104–5, 106
pulsatile character 29
receptor mutations 8
lymphocytic thyroiditis, chronic see autoimmune disease
McCune–Albright syndrome 7, 113–14, 204, 206
macrovascular complications of diabetes 291, 292
magnesium 175–6
deficiency disorders 189, 191
fetal/neonatal 67
postneonatal 183
supplements 208
magnetic resonance imaging (MRI) of brain pituitary 41, 45–6, 85, 315
precocious puberty 110
Majewski syndrome 83
males
andro gens in see androgens
pseudohermaphroditism 49
undermasculinized 51–4, 164
XX 10, 52
see also boys; XY male
malignant tumors see cancer
MAPK and XY cancer 145
Marfan syndrome 94–5
Marshall–Smith syndrome 96
masculinization see virilization
maternal issues see pregnancy
maturity-onset diabetes of the young (MODY) 269–70
characteristics (compared with other forms) 269
classification 270
measurements see tests
medroxyprogesterone, McCune–Albright syndrome 114
medullary thyroid carcinoma 145, 302, 303–4
megalo blastic anemia, thiamine-responsive 271
melanocortin 4 receptor deficiency 257
MELAS syndrome 186
men see males
MEN see multiple endocrine neoplasia
meningitis, pituitary dysfunction 46
menstrual cycle, reference ranges 27
metabolic syndrome 259–60
metabolism
bone see bone
defects/disorders (in general)
adrenal insufficiency due to 166–7
hypoglycemia due to 245–6
nephrogenic diabetes insipidus due to 223, 224
obesity due to 253–5
of hormone target tissue 23
in obesity see obesity
in weight gain, adaptations 257–60
see also specific substrates and metabolites
metabolomics 2
Metaphyseal chondrodysplasia, Jansen type 195, 197
metastases, thyroid cancer 304
metformin
obesity 264
polycystic ovaries 120
methimazole (MMI) 141–2, 143
neonatal 66
microarrays, DNA arrays and 5, 9, 13
microcephalic osteodysplastic primordial dwarfism 83
micronutrient deficiency causing hypothyroidism 136
microvascular complications of diabetes 291–2
mineralocorticoids
administration 173
21-hydroxylase deficiency 162
receptor mutations 172
secretion 154–5
excess, clinical characteristics 155
mitochondrial (DNA) disorders 10–11
diabetes 270
hypocalcemic 186
mitogen-activated protein kinase (MAPK) and thyroid cancer 145
mitotane, adrenocortical tumors 298
molecular biology/genetics 1–14
diagnostics 4–5
novel techniques 13
thyroid cancer 147
therapeutics 13
monoclonal antibody for immunohistoassays 25
monogenic disorders 9–10
monosomies 8
monoclonal antibody for molecular biology/genetics 1–14
mitotane, adrenocortical tumors 298
mitogen-activated protein kinase (MAPK) and thyroid cancer 145
mitochondrial (DNA) disorders 10–11
mutations (gene defects) 5–7, 9–12
multiple endocrine neoplasia (MEN) 301–4
hyperparathyroidism in 195, 302, 304
surveillance and transitional care 304
type 1 195, 196, 301, 301–2, 304
type 2 302, 302–4
medullary thyroid carcinoma and 145, 302, 303
type 2A 195, 196, 303
type 2B 195, 196, 303
type 4 195, 196
mutations (gene defects) 5–7, 9–12
disease and 5–7, 9–12
functional consequences 7
point see point mutations somatic see somatic mutations see also genetic disorders; genetic testing
natriuretic peptides 216–17
necrobiosis lipoidica diabeticorum 291
neurohypophyseal disorders 144–5
neurofibromatosis type I and pheochromocytoma 299–300
neurofibromatosis type I and pheochromocytoma 299–300
neurogenics (central) diabetes insipidus (NPI) 222–3
causes 222–3
chemotherapy 87
central DI and, differentiation 217–18
nephropathy, diabetic 292
neurofibromatosis type I and pheochromocytoma 299–300
neurogenic (central) diabetes insipidus 39–40, 218–22
neurohypophyseal DI, familial autosomal 218
neurohypophysis (posterior pituitary) 31, 212, 310
congenital disorders 39–40
neuroimaging
pituitary 41, 45–6, 85, 315
precocious puberty 110
neurological effects of hypoglycemia (neurolgocerten) 290
immediate 236–7
long term 237, 289
neuropathy, diabetic 292
neurophysin (NP) 211
NPII mutations 218
neurosurgery causing diabetes insipidus 220
newborns see infants
next-generation sequencing 13
nocturnal hypoglycemia 290
nodular hyperplasia
adrenal 171
thyroid 145–6
Noonan syndrome 80–1
growth charts 330
treatment 93
NR5A1 mutations 8, 51–2
nuclear receptors 22–3
obesity 248–65
courses 250–7
clinical/diagnostic approach 250
defining 249–50
endocrine consequences 260
growth rate increase 96–7, 260
long-term risks 261–2
management (incl. comorbidities) 262–5
aims 248
metabolic complications 257–9
identification and screening 260–1
pleiotropic obesity syndromes 250
prevention 265
obstructive sleep apnea, obesity 260
older (aging) adult, reference ranges 27
oligohybrids or sequencing 13
oral contraceptive treatment, polycystic ovaries 119–20
orchidectomy 307
organic acidurias, hypoglycemia 246
orlistat 264
osmolality, serum/plasma 213
osmotic regulation 211–16
osseous heteroplasia, progressive 205, 207
osteoblasts 180
osteoclasts 180–3
osteodystrophy, Albright hereditary 11, 185, 252
osteogenesis imperfecta 181, 200, 201
osteomalacia, tumor-induced 204, 207
osteoporosis 202, 203
osteoporosis 184, 185, 200–2
secondary 202
treatment 202, 208
osteoporosis-pseudoglioma syndrome 201, 208
ovaries
cysts in McCune–Albright syndrome 114
polycystic ovaries 118–21
development disorders 50
failure, primary 124
functional tests 321
tumors 305–6
causing sexual precocity 117
overgrowth syndromes 95–6
ovotesticular disorders of sex development 52
oxidoreductases, P450 see cytochrome
P450 steroidogenic enzymes
oxytocin 40, 211
p53 297
P450 oxidoreductases see cytochrome
P450 steroidogenic enzymes
Paget disease, juvenile 202
painful thyroid 139
pancreas 239–40
endocrine 239
islet cells see islet cells
exocrine 239
panhypopituitarism 40, 82, 125, 324, 325
paraganglioma 298–300, 301
parathyroid gland 177
removal 302, 304
parathyroid gland disorders 186–7, 196–7
age causes 186–7, 196–7
neonatal hypercalcemia in 68
hypocalcemia in 67
parathyroid hormone (PTH) 175, 176–7
excess/deficiency see hyperparathyroidism;
hypoparathyroidism
GNAS1 and 177, 185, 190
imprinting of 11–12
in hypomagnesemia 191
postneonatal 183
receptors 177
mutations 177, 188, 195, 197
resistance 185, 190
parathyroid hormone-related peptide (PTHrP) 176, 177, 179
postneonatal 183
receptor mutations 177, 188, 195, 197
Patau syndrome 80
pegvisomant 86
pendrin 132
penetration (of genotype) 7–8
incomplete 7
peptide hormones, biosynthesis/storage/secretion 15–16
periodic paralysis, thyrotoxic 144
petrosal sinus sampling, CRH test in conjunction with 317, 318
pharmacogenetics 13
pharmacogenomics 2
pharmacotherapy see drug therapy
phenotype
expressivity (of genotype) 7–8
sex-influenced 8
pheochromocytoma 298–300, 302
**Index**

PHEX 179
phosphate binders 208
metabolism 175–6
fetal/neonatal 67
postneonatal 183
metabolism, disorders 202–4
in diabetic ketoacidosis 285
normal values 341
supplements 206, 208
see also hyperphosphatemia; hypophosphatemia
physical examination see examination
pituitary gland (hypophysis) 31–47, 310–18
disorders
acquired 44–6
combined hormone deficiencies 40–2, 58
congenital 31–43
hypoglycemia 244
in infants 57–8
tumors see tumors
MRI 41, 45–6, 85
normal values (for hormones) 337–8
structure and function 31–2
tests (of function) 310–18
indications 311
tumors see tumors
see also adenohypophysis;
hypothalamo-pituitary–adrenal axis;
hypothalamo-pituitary–gonadal axis;
hypothalamo-pituitary–thyroid axis;
neurohypophysis
placenta and thyroid hormones 131
pluriglandular autoimmune syndrome see autoimmune polyendocrine/ polyglandular syndrome
point mutations 6
screening 4
polyclonal antibody for immunoassays 24
polycystic ovaries 118–21
polydipsia 223–4
diagnosis in 217
polygenic disorders 12
polyglandular autoimmune syndrome see autoimmune polyendocrine/ polyglandular syndrome
polymerase chain reaction (PCR) 4
polymorphisms (genetic) 2, 5, 7
single-nucleotide (SNPs) 3, 5, 7, 12
polyostotic fibrous dysplasia 206
polyuria, presentation with 217
positron emission tomography, hyperinsulinism 243
posture and reference ranges 27
potassium administration in diabetic ketoacidosis 284–5
normal values 341
Prader–Willi syndrome 11, 81–2, 252
growth charts 335–6
management 92
pregnancy (maternal issues) antithyroid medication see antithyroid medication
history-taking, in hypoglycemia 232
obesity (in child’s later life) related to 253
thyrotropin receptor antibodies 64, 131
see also fetus; placenta
premature infant obesity and 253
thyroid abnormalities 61
prenatal diagnosis combined pituitary hormone deficiencies 42
21-hydroxylase deficiency 57, 162
primordial short stature syndromes 83
profiling, endocrine 28–9
progeria, neonatal 83
progestagen added to estrogen in pubertal delay 127
progesterone, normal values 340
progressive osseous heteroplasia 205, 207
prohormone convertase 1 deficiency 257
prolactin (PRL) elevated levels see hyperprolactinemia receptors 18–19
pro-opiomelanocortin (POMC) 154
deficiency 256–7
peptides derived from 154
short stature 87–8
puberty 99–128
constitutional delay see constitutional delay of puberty
delay/failure 120–7, 317
defining 107–8
differential diagnosis 122
investigations and assessment 89, 120–1, 317
delaying insulin and hormonal treatment 224
early/precocious (sexual precocity) 108–20
central (CPP) 108, 111, 112, 113, 161
defining 107
etiology 108
investigation/diagnosis 89, 109, 110, 317
problems associated with 117
tall stature 97
treatment 111–13
endocrine changes 104–7
ontogeny 106–7
limits of normal development 107–8
physical changes 100–3
growth 71, 100, 103
sex steroid priming (for induction of) 311
see also adolescents
pubic hair development 100
boys 100, 101
girls 100, 102
pulmonary disorders, hyponatremia 226
pulse analysis 28, 29
pycnodysostosis (pyknodysostosis) 202, 203
quantitative CT of bone density 185
Rabson–Mendenhall syndrome 271
race/ethnicity and obesity 250, 253
radioimmunoassays 24
radioiodine (I-131) therapy hyperthyroidism 143–4
remnant ablation (after thyroid cancer surgery) 148–9
radioisotope imaging (scintigraphy) parathyroid 198
thyroid cancer 147
radiology see imaging radiotherapy effects pituitary dysfunction 46
pubertal precocity 108
short stature 87–8
evaluation 89–90
RANK and RANKL 180–3
recessive disorders autosomal 9–10
X-linked 10
5a-reductase deficiency 52
reference change values 28
reference ranges (normal values) 26–8, 337–42
renal … see kidney
renin 154–5
plasma measurements 156
normal values (PRA) 339
renin–angiotensin–aldosterone system 154–5
volume regulation and 216
RET and thyroid cancer 145, 302–3
retinoblastoma 12
retinopathy, diabetic 292
reverse transcriptase polymerase chain reaction (RT-PCR) 4
rhythms, endocrine 16
Richardson–Kirk syndrome 187
rickets 191
hypophosphatemic 204, 205
vitamin D deficiency 191, 191–2
vitamin D-dependent 193
RNA analysis (for diagnostic use) 4–5
Russell–Silver syndrome 81
growth charts 331

safety considerations in tests 309–10
salt-wasting cerebral 220, 228, 229
21-hydroxylase deficiency 161
sample collection (for hormone measurements) 310
blood 28, 310
Sanjad–Sakati syndrome 187
Schmidt syndrome 135, 166
scintigraphy see radioisotope imaging
sclerosis 203
Seckel syndrome 83
secretion (endogenous), assessment 28
selenoprotein iodothyronine
monodeiodinases 133
sensitivity of assays 25–6
septo-optic dysplasia 42, 219, 315
serine kinase receptors 16
Sertoli cell tumors 306
sex chromosomes
gene disorders linked to see X-linked disorders
numerical abnormalities 51
tall stature 94
sex cord stromal tumors
ovarian 305
testicular 306
sex development disorders (incl. ambiguous genitalia and intersex) 49–55
causes 50–4
classification 50
clinical presentation 49
investigations 54–5
terminology 49
web links and guidelines 69
normal 49–50
see also puberty
sex-influenced phenotype 8
sex region-determining Y (SRY) factor 10, 48–9
disorders relating to 10, 52
sex steroids (gonadal administration
delayed puberty 125
short stature 91–2
tall stature 98

measurements 320–1
normal values 340–1
priming 311
puberty 105–6
excess causing precocious puberty 117
see also estrogen; testosterone
sexual precocity see puberty
short stature 36, 40, 76–93
categorization 76
constitutional 76, 86–7
epidemiology 77
evaluation 89–90
management 90–2, 126
psychosocial deprivation as cause of 46, 86
SHORT syndrome 82
short-chain 3-hydroxyacyl-CoA dehydrogenase (SCAD) deficiency 142, 285
SHOX insufficiency 78, 87, 93
three or more copies 94
sibutramine 264
Silver–Russell syndrome see Russell–Silver syndrome
Simpson–Golabi–Behmel syndrome 96
single gene disorders see monogenic disorders
single-nucleotide polymorphisms (SNPs) 3, 5, 7, 12
skeletal dysplasias 83–4, 180
Eiken 188
treatment 93–4
skeletal maturity, assessment 73
skin
insulin injections and local effects on 288
type 1 diabetes-related lesions 291
skinfold measurements 72, 249
sleep disorders in obesity 260
reference ranges 27
small for gestational age 83
GH insensitivity and 86
treatment for short stature 93
socioeconomic factors, obesity 253
sodium disturbances see hypernatremia; hyponatremia
normal values 341
sodium bicarbonate in diabetic ketoacidosis 285
soft tissue calcification 204–5, 207
somatic mutations and cancer 12
thyroid cancer 145
somatostatin 71
analogues, with GH-secreting adenomas 98
Sotos syndrome 96
SOX9 49, 51
duplications/mutations 51
specificity of assays 25
SRY see sex region-determining Y factor
standard deviation scores, growth assessment 75
STAT5B mutations 19, 43, 86
stature see height; short stature; tall stature
steatohepatitis 259
steatosis 259
steroid (hormones) 16
biosynthesis 53, 152–65
genetic disorders see genetic disorders
regulation 152–8
catabolism 155
defective actions causing hypergonadotropic hypogonadism 124
measurements, plasma and urine 156
steroidogenic factor 1 (NR5A1) gene mutations 8, 51–2
steroidogenic regulatory protein (StAR) and lipid CAH 158
stimulation tests 30
stomach surgery for weight loss 264–5
stress doses of glucocorticoids 173
suppression tests 30
SURL mutations 13, 240, 242
surgery
diabetes insipidus following 220–1
following neurosurgery 220
diocrine tumors
pheochromocytoma 300
of type 1 multiple endocrine neoplasia 302
hyperthyroidism 143
obesity 264–5
osteoporosis 202
ovarian tumor 305
pituitary ACTH-producing tumors 170
testicular tumor 307
thyroid cancer 148, 303–4
surveillance in multiple endocrine neoplasia 304
synacthen (ACTH 1–24); Cosyntropin test 157, 318–19
syndrome-specific growth charts 75, 325–36
syndromic associations (incl. genetic syndromes)
diabetes 268
gonadal dysgenesis 51
hypergonadotropic hypogonadism 124
hypogonadotropic hypogonadism 123
hypothalmo-pituitary developmental disorders 35
insulin resistance 271
obesity 250, 252
short stature and growth failure 78–83
tall stature 94–5

tumors
malignant (cancer) 12
pheochromocytoma 299
systemic disorders, hypocalcemia 193–5
tall stature 94–8
investigations 97, 321, 323
management 97
primary 94–6
secondary 96–7
tamoxifen, McCune–Albright syndrome 114
Tanner stages 100, 101–2
FSH values 337
LH values 338
teenagers see adolescents
teratomas, ovarian 305
test(s) (measurements/assays) of hormones 23–8
accuracy 26
clinical implications 29
patient preparation 310
reference change values 28, 337–42
reference ranges 26–8
safety considerations 309–10
sample collection see sample collection
sensitivity 25–6
specificity 25
testicular feminization (complete androgen insensitivity syndrome) 54, 320
testis (testicles) 320–1
development
disorders 50, 51–2
hypergonadotropic hypogonadism due to 124
see also ovotesticular disorders
puberty 100
functional tests 320–1
tumors 306–7
testis-specific protein Y-encoded (TSPY) 305
testolactone, McCune–Albright syndrome 114
testosterone
administration
delayed puberty 125–6
short stature 92
tall stature 92
measurements 320–1
normal values 340
sex steroid priming with 311
synthesis 53
infants, deficient 64
puberty 71, 105
thalassemia, pituitary dysfunction 46
thelarche, premature (and its variants) 115–16
investigations 110
thiamine-responsive megaloblastic anemia syndrome 271
thiazide diuretics in nephrogenic diabetes insipidus 223
thiazolidinediones, polycystic ovaries 120
thirst 216–17
see also adipsia; hypodipsia; polydipsia
three (3; triple) A syndrome 167
three (3; triple) M syndrome 82
threonine kinase receptors 16
thyroglobulin (Tg) 130, 131–2, 133, 147
antibodies to 135, 138, 140, 141
measurement 147
thyroglossal cysts and thyroid cancer 146
thyroid gland 129–50
infants 63
infancy 149
post-thyroidectomy 149
receptor, antibodies 64, 131, 133, 136, 140, 141
regulation of function 133
thyroid hormones
action 134
maturation of 130
resistance to 136–7, 138
bone and 131
brain development and 130–1
brown adipose tissue and 131
excess/deficiency see hyperthyroidism; hypothyroidism
genesis 131–2
inborn errors 136
metabolism 133–4
normal values 340
receptors 134
mutations 137
replacement therapy 138
infancy 149
post-thyroidectomy 149
translocation 133
thyroid peroxidase (TOP) 132
antibodies 135–6, 138, 139, 140, 141
thyroid-stimulating hormone see thyrotropin
thyroid storm 144
thyroiditis
acute 139
acute and subacute 139
autoimmune see autoimmune disease
thyrotoxicosis
life-threatening complication (thyroid storm) 144
periodic paralysis 144
tall stature 97
without hyperthyroidism 139, 140
thyrotopin (thyroid-stimulating hormone; TSH) 36, 133
deficiency (decreased synthesis or secretion) 63
cancer therapy 88, 89
infantile 58, 63
isolated 36–7
maternal antibodies 64
measurements
hyperthyroidism 141
hypothyroidism 137
normal values 337
receptor, antibodies 64, 131, 133, 136, 140, 141
resistance 63
thyrotropin-releasing hormone (TRH) in maturation of hypothalamo–pituitary–thyroid axis 130
tests 316, 321
thyroxine (T4) congenital hypothyroidism levels 62, 63
replacement therapy 65
in development and maturation of hypothalamo–pituitary–thyroid axis 130
functions 130–1
metabolism 133
normal values 340
premature infant levels 61
replacement therapy 138
infants 149
synthesis (genesis) 131–2
thyroxine-binding globulin 130, 133, 141
TNM staging, thyroid cancer 148
transcription 3
transcription factors 3
mutations 3, 7, 8
transcriptomics 2
transitional care diabetes 293–4
multiple endocrine neoplasia 304
translocations 8
transsphenoidal surgery, pituitary ACTH-producing adenoma 170
trauma (injury), head see head
tri-iodothyronine (T3) embryonic/fetal 130
metabolism 133
normal values 340
receptors 23
synthesis 132
trinucleotide repeat disorders 6
triple (3) A syndrome 167
triple (3) M syndrome 82
triplet (trinucleotide) repeat disorders 6
triptorelin, precocious puberty 111, 112
trisomies 8
cromosome 13 (Patau syndrome) 80
cromosome 18 (Edward syndrome) 80
cromosome 21 see Down syndrome
TSPY (testis-specific protein Y-encoded), gene 305
tubular acidosis, distal renal 193
tumor(s) (neoplasms) 296–307
adrenal 170–1, 171, 297–300
cortical 170–1, 171, 297–9, 302
medullary 298–300
sexual precocity 117
brain, causing diabetes insipidus 219–20
see also hypothalamic–pituitary (subheading below)
gonadal 305–6
sexual precocity 117
hypothalamic–pituitary (incl. anterior pituitary) 44, 302
ACTH deficiency (adrenal insufficiency) with 168
ACTH-producing 168, 170
GH-producing 96, 97–8
Leydig cell 117, 306
malignant see cancer
osteomalacia induced by 204, 207
parathyroid 198
thyroid 144–9, 300–1
tumoral calcinosis
hyperphosphathemic familial 204, 207
normophosphatemic familial 205
Turner syndrome 78–80, 78–9
growth charts 325
hypergonadotropic hypogonadism 124
management 92–3
tyrosine kinase receptors 16
ultrasound
polycystic ovaries 119
thyroid 147
unconsciousness, hypoglycemia 291
uniparental disomy 11
urine
hormone measurements 23–30
sample collection 310
steroids 156
ketones in
insulin supplementation related to 287
testing 281
Usher syndrome 242
vaginal development in complete androgen insensitivity syndrome 54
van Buchem disease 203
vascular complications of diabetes 291–2
vasculitis, systemic, antithyroid drug-induced 142
vasopressin (arginine vasopressin; ADH; antidiuretic hormone) 39–40, 211–16
appropriate increased secretion 227–8
biological actions 215–16
deficiency 217–18
excess 225
gene 211
inappropriate secretion (SIADH) 225, 228
chemotherapy-induced 76
distinction from cerebral salt wasting and diabetes insipidus 228, 229
metabolism 215
receptors 215–16
mutations 215, 223
regulation of secretion 212–14
in water deprivation test, response 218
see also desmopressin
virilization (masculinization)
males 50–1
adrenal tumors 171
congenital adrenal hyperplasia, scoring 49
21-hydroxylase deficiency 161
multiple P450 enzyme deficiency 164
males, deficient 51–4, 164
vitamin B1 (thiamine)-responsive megaloblastic anemia syndrome 271
vitamin D 177–8
administration 207
pseudohypoparathyroidism 190
vitamin D deficiency 193, 207
deficiency 191–3
neonatal hypocalcemia in 67, 183
rickets 191, 191–2
treatment 193, 207
metabolic disorders 193
hyperparathyroidism associated with 197, 198
postneonatal 183
receptor (VDR) defects 23, 193, 194
volume (intravascular) sensing and effector pathways 216–17
see also hyperparathyroidism; hypovolemia
von Hippel–Lindau (VHL) disease 301
pheochromocytoma 299, 301
von Recklinghausen disease
(neurofibromatosis type I) and pheochromocytoma 299–300
waist circumference 84
obesity/adiposity 249, 260
water 210–29
balance 210–29
disorders 217–29
deprivation test 217, 218
excess free water losses other than diabetes insipidus 224
intoxication 229
see also dehydration; fluid
Weaver syndrome 96
weight
at birth, low, and obesity 253
loss, surgery for 264–5
measurement 72
metabolic adaptations to gain in 257–60
see also growth charts
WHO see World Health Organization
Wiedemann–Beckwith (Beckwith–Wiedemann) syndrome 96, 241, 297
Williams–Beuren syndrome 107, 198, 295
Wolfram syndrome (DIDMOAD) 10–11, 40, 218–19, 271
Wolman disease 167
women see females
World Health Organization (WHO) classification
ovarian tumors 305
testicular tumors 306
WT1 49
mutations 51
X-linked disorders 10
obesity syndromes 252
xanthomatosis, primary 167
46XX female 49
sex development disorders 50, 50–1
46XX male 10, 52
47XXY (Klinefelter) syndrome 52, 94, 124–5
66XXY syndromes 80
46XY female and (XY infant with ambiguous genitalia) 10, 49
investigations 54–5
management 55
46XY male 49
sex development disorders 50, 51–4
Y chromosome
disorders linked to mutations 10
inactivation 11
z (standard deviation) scores, growth assessment 75
zona fasciculata 152
zona glomerulosa 152
zona reticularis 152